SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders
SciSparc (Nasdaq: SPRC) and Clearmind Medicine have filed an international patent application for a novel treatment targeting eating disorders, including anorexia and bulimia. The treatment combines 3-Methylmethcathinone (3-MMC) with SciSparc's Palmitoylethanolamide (PEA).
The collaboration aims to address the complex neurobiological and psychological aspects of eating disorders, which are among the top ten leading causes of disability in young women. Recent statistics show that eating disorders affect up to 70 million people globally, with prevalence rates increasing from 3.4% to 7.8% between 2000 and 2018, particularly among children and adolescents.
SciSparc (Nasdaq: SPRC) e Clearmind Medicine hanno presentato una domanda di brevetto internazionale per un nuovo trattamento mirato ai disturbi alimentari, tra cui anoressia e bulimia. Il trattamento combina il 3-Metilmetcatinone (3-MMC) con il Palmitoiletanolamide (PEA) di SciSparc.
La collaborazione si propone di affrontare gli aspetti neurobiologici e psicologici complessi dei disturbi alimentari, che rappresentano una delle prime dieci cause di disabilità tra le giovani donne. Le statistiche recenti mostrano che i disturbi alimentari colpiscono fino a 70 milioni di persone nel mondo, con tassi di prevalenza in aumento dal 3,4% al 7,8% tra il 2000 e il 2018, in particolare tra bambini e adolescenti.
SciSparc (Nasdaq: SPRC) y Clearmind Medicine han presentado una solicitud de patente internacional para un nuevo tratamiento dirigido a los trastornos alimentarios, incluyendo anorexia y bulimia. El tratamiento combina 3-Metilmetcatinona (3-MMC) con Palmitoiletanolamida (PEA) de SciSparc.
La colaboración tiene como objetivo abordar los complejos aspectos neurobiológicos y psicológicos de los trastornos alimentarios, que se encuentran entre las diez principales causas de discapacidad en mujeres jóvenes. Las estadísticas recientes muestran que los trastornos alimentarios afectan hasta a 70 millones de personas en todo el mundo, con tasas de prevalencia que aumentaron del 3,4% al 7,8% entre 2000 y 2018, especialmente entre niños y adolescentes.
SciSparc (나스닥: SPRC)와 Clearmind Medicine이 섭식 장애, 특히 거식증과 폭식증을 대상으로 하는 새로운 치료법에 대해 국제 특허 출원을 제출했습니다. 이 치료법은 3-메틸메스카틴온(3-MMC)과 SciSparc의 팔미토일에탄올아마이드(PEA)를 결합한 것입니다.
이번 협력은 젊은 여성의 주요 장애 원인 10가지 중 하나인 섭식 장애의 복잡한 신경생물학적 및 심리적 측면을 해결하는 것을 목표로 합니다. 최근 통계에 따르면 섭식 장애는 전 세계 7천만 명에 이르며, 2000년에서 2018년 사이 유병률이 3.4%에서 7.8%로 증가했으며, 특히 아동과 청소년 사이에서 두드러집니다.
SciSparc (Nasdaq : SPRC) et Clearmind Medicine ont déposé une demande de brevet internationale pour un nouveau traitement ciblant les troubles alimentaires, notamment l’anorexie et la boulimie. Ce traitement associe le 3-Méthylméthcathinone (3-MMC) au Palmitoyléthanolamide (PEA) de SciSparc.
Cette collaboration vise à prendre en charge les aspects neurobiologiques et psychologiques complexes des troubles alimentaires, qui figurent parmi les dix principales causes d’invalidité chez les jeunes femmes. Les statistiques récentes indiquent que les troubles alimentaires affectent jusqu’à 70 millions de personnes dans le monde, avec un taux de prévalence passant de 3,4 % à 7,8 % entre 2000 et 2018, notamment chez les enfants et les adolescents.
SciSparc (Nasdaq: SPRC) und Clearmind Medicine haben einen internationalen Patentantrag für eine neuartige Behandlung von Essstörungen, einschließlich Anorexie und Bulimie, eingereicht. Die Behandlung kombiniert 3-Methylmethcathinon (3-MMC) mit SciSparcs Palmitoylethanolamid (PEA).
Die Zusammenarbeit zielt darauf ab, die komplexen neurobiologischen und psychologischen Aspekte von Essstörungen zu adressieren, die zu den zehn häufigsten Ursachen für Behinderungen bei jungen Frauen gehören. Aktuelle Statistiken zeigen, dass Essstörungen weltweit bis zu 70 Millionen Menschen betreffen, mit einer Zunahme der Prävalenz von 3,4 % auf 7,8 % zwischen 2000 und 2018, insbesondere bei Kindern und Jugendlichen.
- Filed international patent application for novel eating disorder treatment
- Addresses a large market with 70 million affected patients globally
- Targets conditions with increasing prevalence (3.4% to 7.8% growth)
- Early-stage development with no proven efficacy yet
- Patent application filed but not yet granted
TEL AVIV, Israel, April 25, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) has led to the filing of a new international patent application for a proprietary treatment targeting anorexia, bulimia and other eating disorders.
The patent application covers the use of 3-Methylmethcathinone (3-MMC) in combination with SciSparc’s Palmitoylethanolamide (“PEA”). This innovative combination aims to address the complex neurobiological and psychological factors associated with eating disorders, offering a potential new avenue for treatment.
Eating disorders are serious mental health conditions that negatively impact an individual’s health, emotions, and ability to perform daily functions. Eating disorders are among the top ten leading causes of disability among young women and have one of the highest mortality rates compared to other mental disorders. According to recent studies, up to 70 million people globally are affected by eating disorders, with significant increases observed among children and adolescents. Global eating disorder prevalence increased from
About SciSparc Ltd. (Nasdaq: SPRC):
SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation and SCI-210 for the treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seed oil-based products on Amazon Marketplace.
About Clearmind Medicine Inc. (“Clearmind”)
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
Clearmind’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. Clearmind intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Common shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, SciSparc is using forward-looking statements when it discusses the potential of its proprietary treatment to treat anorexia, bulimia and other eating disorders. Because such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 24, 2025, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055
FAQ
What is the new treatment being developed by SciSparc (SPRC) for eating disorders?
How many people are affected by eating disorders according to SciSparc's (SPRC) research?
What is the significance of SciSparc's (SPRC) patent application for eating disorder treatment?
What compounds are included in SciSparc's (SPRC) patent application for eating disorders?
